Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 320 participants.

Also called NCT04419779

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Fractyl Health Inc. (from the registry)
Registry
  • NCT NCT04419779
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Ireland, Italy, Netherlands, Switzerland, United Kingdom (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT04419779. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-08 (actual); primary completion 2026-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
Acronym
REVITALIZE 1
Intervention (Device)
Duodenal Mucosal Resurfacing (DMR)
Intervention (Device)
Duodenal Mucosal Resurfacing (Sham)
Lead sponsor
Fractyl Health Inc. (class: industry)

Record details

Record id
cardio:ct-nct04419779
Content hash
932d80360eb90c3e58788d7702dc16caf85e95a3bbe57d5ff5bac42035b21770